IndustryCompany release

Evaxion refocuses on cancer vaccines as EVX-04 heads toward phase 1 filing

Evaxion · Thu 19 Nov 2026

The Nasdaq-listed company is narrowing its pipeline to immuno-oncology, reporting a $3.5M third-quarter net loss and a cash runway stretching toward the end of 2027.

Evaxion (NASDAQ: EVAX) announced on 19 November 2026 that it is shifting its strategy towards immuno-oncology. The company will concentrate on three cancer vaccine candidates: the personalised vaccine EVX-01 for melanoma, and the off-the-shelf vaccines EVX-04 for acute myeloid leukaemia (AML) and EVX-05.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release: Evaxion ↗

Article written by VigiEye from the official source (Evaxion). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →